LivaNova PLC (LIVN) stock plummeted 5.27% in Tuesday's pre-market trading session, underperforming the broader market. The medical technology company reported mixed fourth-quarter results, with earnings beating estimates but revenue missing expectations.
For Q4, LivaNova reported adjusted earnings per share of $0.81, slightly above the consensus estimate of $0.80. However, revenue came in at $321.8 million, missing analysts' expectations of $324.1 million. The company's full-year revenue grew by 3.77% compared to the previous year.
Furthermore, LivaNova's 2025 guidance disappointed investors. The company expects adjusted EPS in the range of $3.65 to $3.75, slightly below the FactSet consensus estimate of $3.66. Revenue growth is projected to be between 5% and 6% on a constant-currency basis and 6% to 7% on an organic basis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.